Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Pancreatic Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

117 recruiting trials for Pancreatic Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 117 Pancreatic Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 35% (23 studies); the largest phase groups are Phase 1: 23, Phase 2: 22, Phase 1 / Phase 2: 15, Phase 3: 4.

Research is led by National Cancer Institute (NCI) (4), Fudan University (3), Zhejiang University (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Magnetic resonance imaging (diagnostic_test, 4 trials), followed by Cyclophosphamide, Fludarabine.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
117
Total Trials
117
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Track Pancreatic Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGNCT01102569

Pancreatic Cancer Genetics

The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly...

Sponsor: Columbia UniversityEnrolling: 1001 location
RECRUITINGNCT02838836

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery....

Sponsor: University of Missouri-ColumbiaEnrolling: 6201 location
RECRUITINGNCT03787056

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric...

Sponsor: Hospices Civils de LyonEnrolling: 41017 locations
RECRUITINGPhase 1 / Phase 2NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of...

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This...

Sponsor: National Cancer Institute (NCI)Enrolling: 1101 location
RECRUITINGPhase 1 / Phase 2NCT06298916

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and...

Sponsor: Lantheus Medical ImagingEnrolling: 265 locations
RECRUITINGPhase 2NCT06196788

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic...

Sponsor: Fudan UniversityEnrolling: 301 location
RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGNCT07408505

Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer

Cancer anorexia-cachexia syndrome is a common and severe complication in patients with advanced cancer, with a particularly high prevalence in pancreatic cancer. It is associated...

Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 561 location
RECRUITINGNCT06148298

Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer

The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal...

Sponsor: University of Central FloridaEnrolling: 241 location
RECRUITINGNCT07605819

Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer...

Sponsor: Cosomil, Inc.Enrolling: 100001 location
RECRUITINGPhase 2NCT07282912

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With...

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with...

Sponsor: Yale UniversityEnrolling: 541 location
RECRUITINGPhase 1NCT07630961

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DFC413, and in Part 2 compare to...

Sponsor: Novartis PharmaceuticalsEnrolling: 661 location
RECRUITINGNCT03410394

Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)

This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine...

Sponsor: Central Hospital, Nancy, FranceEnrolling: 30001 location
RECRUITINGPhase 1 / Phase 2NCT06921928

Study for AZD4360 in Participants With Advanced Solid Tumours

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally...

Sponsor: AstraZenecaEnrolling: 11718 locations
RECRUITINGPhase 1 / Phase 2NCT07523529

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker...

Sponsor: Beijing BiotechEnrolling: 721 location
RECRUITINGPhase 1 / Phase 2NCT06799637

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...

Sponsor: Evopoint Biosciences Inc.Enrolling: 35020 locations
RECRUITINGPhase 1 / Phase 2NCT07284277

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based...

Sponsor: Clinica Universidad de Navarra, Universidad de NavarraEnrolling: 305 locations
RECRUITINGNCT06867172

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic...

Sponsor: Carol Davila University of Medicine and PharmacyEnrolling: 661 location
RECRUITINGNCT06666803

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)

Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived...

Sponsor: IHU StrasbourgEnrolling: 602 locations
RECRUITINGNCT03250078

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic...

Sponsor: Nuvance HealthEnrolling: 2001 location
RECRUITINGNCT05191940

Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)

This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.

Sponsor: EBG MedAustron GmbHEnrolling: 301 location
RECRUITINGPhase 4NCT06099119

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

\- This will a be an open label, multicentre, randomized, controlled study in patients with unresectable pancreatic cancer, locally advanced or metastatic, with significant weight...

Sponsor: Hospital Clinico Universitario de SantiagoEnrolling: 1004 locations
RECRUITINGPhase 3NCT06953999

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus...

Sponsor: AkesoEnrolling: 9993 locations
RECRUITINGPhase 1NCT06723236

A Study of MGC028 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of...

Sponsor: MacroGenicsEnrolling: 1247 locations
RECRUITINGPhase 2NCT06659705

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could...

Sponsor: Institut CurieEnrolling: 351 location
RECRUITINGPhase 2NCT06345079

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce...

Sponsor: Australasian Gastro-Intestinal Trials GroupEnrolling: 7812 locations
RECRUITINGNCT07183280

Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas

To establish and maintain a reliable multicenter real-world database for pancreatic SPN, providing high-quality data and evidence-based support for clinical/translational research.

Sponsor: Fudan UniversityEnrolling: 20001 location
RECRUITINGNCT07015580

The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis

There are more than 700 different bacteria colonized in human oral cavity, which are collectively referred to as oral microbiota. Emerging evidence suggests that oral microbiota...

Sponsor: Ruijin HospitalEnrolling: 3601 location
RECRUITINGPhase 1NCT05687123

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic...

Sponsor: National Cancer Institute (NCI)Enrolling: 2410 locations
RECRUITINGNCT06164769

Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery

Pancreatic enucleation could preserve more healthy pancreatic tissues and functions with a low recurrence risk. However, conventional enucleation can cause significant...

Sponsor: Zhejiang UniversityEnrolling: 301 location
RECRUITINGPhase 1NCT06835569

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

Sponsor: Alterome Therapeutics, Inc.Enrolling: 44812 locations
RECRUITINGPhase 1NCT04361708

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as...

Sponsor: University of ChicagoEnrolling: 541 location
RECRUITINGNCT07647250

Pilot Study to Evaluate Targeted Physical Activity Among Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy

Patients with pancreatic cancer receiving neoadjuvant chemotherapy often experience functional decline, treatment interruptions, and clinical deterioration, and these risks may be...

Sponsor: University of Illinois at ChicagoEnrolling: 251 location
RECRUITINGPhase 2NCT06149689

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer.

Sponsor: Fudan UniversityEnrolling: 301 location
RECRUITINGPhase 2NCT01174121

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large...

Sponsor: National Cancer Institute (NCI)Enrolling: 3321 location
RECRUITINGNCT06966440

Adjuvant Pancreatic Therapy Guided by MRD

Pancreatic adenocarcinoma (PAAD) is a leading cause of cancer-related deaths worldwide. Although surgical resection can be curative, the 5-year overall survival (OS) rate after...

Sponsor: Ruijin HospitalEnrolling: 8561 location
RECRUITINGPhase 2NCT04858334

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in...

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been...

Sponsor: National Cancer Institute (NCI)Enrolling: 15220 locations
RECRUITINGNCT06043921

Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel

This is a multicenter, prospective, observational study to evaluate the utility of the Invitae Personalized Cancer MonitoringTM assay for patients with resectable and unresectable...

Sponsor: Invitae CorporationEnrolling: 1501 location
RECRUITINGNCT05724992

Familial Pancreatic Cancer PROPHilation Program in Italy

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the...

Sponsor: Associazione Italiana per lo Studio del PancreasEnrolling: 30001 location
RECRUITINGPhase 1NCT03454035

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 451 location
RECRUITINGNCT07072143

An International Study on Pediatric Patients With Rare Tumors.

The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.

Sponsor: Azienda Ospedaliera di PadovaEnrolling: 62501 location
RECRUITINGPhase 2NCT06453486

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy...

The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main...

Sponsor: University Health Network, TorontoEnrolling: 432 locations
RECRUITINGPhase 2NCT06951997

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 331 location
RECRUITINGNCT07660627

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early...

Sponsor: Masaryk Memorial Cancer InstituteEnrolling: 341 location
RECRUITINGNCT03637569

The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer

In this study, the investigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and GB...

Sponsor: Samsung Medical CenterEnrolling: 10001 location
RECRUITINGPhase 1NCT07189195

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic,...

This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue,...

Sponsor: University of California, DavisEnrolling: 521 location
RECRUITINGNCT04276857

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally...

Sponsor: University of SaskatchewanEnrolling: 272 locations
RECRUITINGNCT03568630

Blood Markers of Early Pancreas Cancer

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in...

Sponsor: University of NebraskaEnrolling: 12501 location
RECRUITINGNCT06602037

ImmunoPET Imaging of Pancreatic Cancer

Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a...

Sponsor: RenJi HospitalEnrolling: 901 location

Showing 50 of 117 trials.Search all Pancreatic Cancer trials

Frequently Asked Questions

There are currently 117 clinical trials for Pancreatic Cancer, with 117 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Pancreatic Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Pancreatic Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.